Brought to you by 
Neurocrine licenses up to four Voyager neuro programs in $1.9bn collaboration; deal restructured
20 Jun 2019
Executive Summary
Neurocrine Biosciences Inc. and Voyager Therapeutics Inc. will collaborate on the development of up to four Voyager neurological disease candidates. The deal includes two adeno-associated virus (AAV) potential gene therapies--VYAADC, a DOPA decarboxylase stimulant in Phase II for Parkinson’s disease (PD) and preclinical VYFXN01, a frataxin agonist for Friedreich’s ataxia (FA)--plus two yet-to-be-determined discovery programs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neurocrine licenses up to four Voyager neuro programs in $1.9bn collaboration; deal restructured
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice